Human Erythropoietin/EPO Quantikine ELISA Kit, RUO Summary
4.5 hours (Benchtop Protocol) or 2.5 hours (Shaker Protocol)
Sample Type & Volume Required Per Well
Serum (100 uL), EDTA Plasma (100 uL)
2.5 - 200 mIU/mL (Serum, EDTA Plasma)
Natural and recombinant human Epo.
< 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
Interference observed with other substances.
The Quantikine® Human Epo ELISA uses a monoclonal antibody and polyclonal antibody conjugate in a sandwich ELISA format. The assay is designed to measure Epo levels in serum or EDTA plasma in less than 4.5 hours, or less than 2.5 hours using the shaker protocol.
Benchtop Protocol Precision (Precision within an assay) Four samples of known concentration were tested thirty times to assess intra-assay precision
Shaker Protocol Precision (Precision between assays) Four samples of known concentration were tested in thirty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using three lots of components
Serum, EDTA Plasma
The recovery of human Epo spiked to levels throughout the range of the assay was evaluated in 10 serum and plasma samples.
|Plasma (EDTA)||Benchtop||51.8 mlU/mL||102%|
Five matched serum and plasma specimens containing elevated Epo concentrations were diluted with Specimen Diluent and assayed using the Quantikine Human Epo ELISA. Diluted specimens demonstrated very good linearity when compared to neat concentrations of Epo.
Human Epo ELISA Benchtop Protocol Standard Curve
Human Epo ELISA Shaker Protocol Standard Curve
Preparation and Storage
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Erythropoietin (Epo), a glycoprotein (~30,400 Daltons) produced primarily by the kidney, is the
principal factor regulating red blood cell production (erythropoiesis) in mammals. Renal
production of Epo is regulated by changes in oxygen availability. Under conditions of hypoxia,
the level of Epo in the circulation increases and this leads to increased production of red blood
The over-expression of Epo may be associated with certain pathophysiological conditions (1,
2). Polycythemia exists when there is an overproduction of red blood cells (RBCs). Primary
polycythemias, such as polycythemia vera, are caused by Epo-independent growth of
erythrocytic progenitors from abnormal stem cells and low to normal levels of Epo are found in
the serum of affected patients. On the other hand, various types of secondary polycythemias
are associated with the production of higher than normal levels of Epo. The overproduction of
Epo may be an adaptive response associated with conditions that produce tissue hypoxia, such
as living at high altitude, chronic obstructive pulmonary disease, cyanotic heart disease, sleep
apnea, high-affinity hemoglobinopathy, smoking, or localized renal hypoxia (1, 2). In other
instances, excessive Epo levels are the result of production by neoplastic cells. Cases of
increased Epo production and erythrocytosis have been reported for patients with renal
carcinomas (3), benign renal tumors (4), Wilms' tumors, hepatomas (5), liver carcinomas (6),
cerebellar hemangioblastomas (3, 7, 8), adrenal gland tumors (9), smooth muscle tumors (3, 9),
and leiomyomas (10).
Deficient Epo production is found in conjunction with certain forms of anemias. These include
anemia of renal failure and end-stage renal disease (1, 2, 11), anemias of chronic disorders
[chronic infections (1), autoimmune diseases (1), rheumatoid arthritis (12), AIDS (13),
malignancies (14)], anemia of prematurity (2), anemia of hypothyroidism (2), and anemia of
malnutrition (2). Many of these conditions are associated with the generation of IL-1 and TNF-alpha,
factors that have been shown to be inhibitors of Epo activity (1, 15). Other forms of anemias, on
the other hand, are due to Epo-independent causes and affected individuals show elevated
levels of Epo (2). These forms include aplastic anemias, iron deficiency anemias, thalassemias,
megaloblastic anemias, pure red cell aplasias, and myelodysplastic syndromes.
Entrez Gene IDs:
2056 (Human); 13856 (Mouse); 24335 (Rat)
ECYT5; EP; EPO; epoetin; Erythropoietin; MGC138142; MVCD2
⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.
Citation for Human Erythropoietin/EPO Quantikine ELISA Kit, RUO
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Citation: Showing 1 - 1
C3P3-G1: first generation of a eukaryotic artificial cytoplasmic expression system
Authors: PH Jaïs, E Decroly, E Jacquet, M Le Boulch, A Jaïs, O Jean-Jean, H Eaton, P Ponien, F Verdier, B Canard, S Goncalves, S Chiron, M Le Gall, P Mayeux, M Shmulevitz
Nucleic Acids Res., 2019-03-18;0(0):.
Species: Transgenic Hamster
Sample Types: Cell Culture Supernates